• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination therapy with an SGLT-2 inhibitor and finerenone in DKD: Are we there yet?

作者信息

Georgianos Panagiotis I, Eleftheriadis Theodoros, Liakopoulos Vassilios

机构信息

Section of Nephrology and Hypertension, 1st Department of Medicine, AHEPA Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.

Department of Nephrology, School of Medical Sciences, University of Thessaly, Larissa, Greece.

出版信息

Eur J Clin Invest. 2023 Feb;53(2):e13864. doi: 10.1111/eci.13864. Epub 2022 Sep 6.

DOI:10.1111/eci.13864
PMID:36038512
Abstract
摘要

相似文献

1
Combination therapy with an SGLT-2 inhibitor and finerenone in DKD: Are we there yet?在糖尿病肾病中使用钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂和非奈利酮联合治疗：我们做到了吗？
Eur J Clin Invest. 2023 Feb;53(2):e13864. doi: 10.1111/eci.13864. Epub 2022 Sep 6.
2
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.卡格列净对比非奈利酮对心肾结局的影响：FIDELIO-DKD 探索性事后分析与 CREDENCE 研究结果的比较。
Nephrol Dial Transplant. 2022 Jun 23;37(7):1261-1269. doi: 10.1093/ndt/gfab336.
3
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease.醛固酮受体拮抗剂非奈利酮在糖尿病肾病中的肾脏保护作用。
Endocrinol Metab (Seoul). 2023 Feb;38(1):43-55. doi: 10.3803/EnM.2022.1629. Epub 2023 Feb 27.
4
Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?非奈利酮——作为一种非甾体类盐皮质激素受体拮抗剂，它在治疗糖尿病慢性肾病方面，我们是否已经成功？
Expert Opin Pharmacother. 2021 Jul;22(10):1253-1256. doi: 10.1080/14656566.2021.1904892. Epub 2021 Mar 25.
5
Cardiorenal benefits of mineralocorticoid antagonists in CKD and type 2 diabetes : Lessons from the FIGARO-DKD trial.慢性肾脏病和 2 型糖尿病患者中盐皮质激素受体拮抗剂的心脏肾脏获益：FIGARO-DKD 试验的启示。
Herz. 2022 Oct;47(5):401-409. doi: 10.1007/s00059-022-05138-2. Epub 2022 Sep 12.
6
Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease.非奈利酮：一种新型盐皮质激素受体拮抗剂，可治疗慢性肾脏病。
Curr Opin Nephrol Hypertens. 2022 May 1;31(3):265-271. doi: 10.1097/MNH.0000000000000785. Epub 2022 Feb 14.
7
BP-lowering effects of SGLT-2 inhibitors and finerenone: an indirect comparison in patients with chronic kidney disease and type 2 diabetes.钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂与非奈利酮的降压作用：慢性肾脏病合并2型糖尿病患者的间接比较
Expert Opin Pharmacother. 2024 Feb;25(2):127-130. doi: 10.1080/14656566.2024.2322527. Epub 2024 Feb 26.
8
Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.用盐皮质激素受体拮抗剂非奈利酮改善 2 型糖尿病患者的慢性肾脏病进展。
Diabetes Obes Metab. 2022 Jul;24(7):1197-1205. doi: 10.1111/dom.14696. Epub 2022 Apr 18.
9
Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease.钠-葡萄糖协同转运蛋白 2 抑制剂在糖尿病肾病治疗中的作用及机制。
Front Immunol. 2023 Sep 21;14:1213473. doi: 10.3389/fimmu.2023.1213473. eCollection 2023.
10
Mineralocorticoid Antagonism and Diabetic Kidney Disease.醛固酮拮抗剂与糖尿病肾病。
Curr Diab Rep. 2019 Jan 23;19(1):4. doi: 10.1007/s11892-019-1123-8.

引用本文的文献

1
Slowing the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes Using Four Pillars of Therapy: The Time to Act is Now.运用四大治疗支柱延缓2型糖尿病患者慢性肾脏病的进展：当下即为行动之时。
Drugs. 2024 Nov;84(11):1337-1346. doi: 10.1007/s40265-024-02091-8. Epub 2024 Sep 11.
2
Therapeutic Advances in Diabetic Kidney Disease.糖尿病肾脏疾病治疗进展。
Int J Mol Sci. 2023 Feb 1;24(3):2803. doi: 10.3390/ijms24032803.